Eisai, GE reach R&D deal for Alzheimer's

04/28/2013 | DOTMed.com · AuntMinnie.com (free registration)

GE Healthcare has announced a collaboration with Eisai focused on research and development of treatments for Alzheimer's disease. GE said its candidate PET agent flutemetamol will be used by Eisai in choosing patients for an early-stage study of Eisai's beta-site amyloid precursor protein-cleaving enzyme inhibitor E2609 as a possible treatment for the disease.

View Full Article in:

DOTMed.com · AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC